Administration of human recombinant interferon alpha-2b in paranoid schizophrenia as adjuvant to neuroleptic therapy. Multi-center, randomized, double-blind controlled trial.

Center for Genetic Engineering and Biotechnology (CIGB), Havana City.0 个研究点目标入组 60 人开始时间: 2009年2月11日最近更新: 2024年8月19日

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

•1. Fulfillment of the diagnosis criteria. 2. Patients with 1-month-10-year term of the evolution of disease. 3.15-65 years-old. 4. Patient´s and/or legal guardian´s signed informed consent.

•1. Schizophrenic patients with episodes. 2. Pregnancy or puerperium. 3. Use of any other treatment, which is not foreseen in the study that changes the development of the disease. 4. Women in fertile age, undergoing hormonal contraceptive therapy. 5. Uncompensated chronic sickness (heart failure, liver failure, renal failure, diabetes mellitus [DM]). 6. Autoimmune diseases. 7. Hypersensitivity to the IFN or other type of preparations used in the trial.

发起方

Center for Genetic Engineering and Biotechnology (CIGB), Havana City.